Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Shingrix vaccine linked to lower dementia risk

Analysis based on 14 articles · First reported Aug 25, 2026 · Last updated Aug 28, 2026

Sentiment
30
Attention
4
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study could boost demand for Shingrix, potentially increasing sales for GSK plc and reinforcing its market position in the shingles vaccine market. It may also spur further research into vaccine neuroprotective benefits, influencing pharmaceutical investment and public health recommendations.

Pharmaceuticals Healthcare

A large observational study published in Annals of Internal Medicine found that older adults who received the Shingrix shingles vaccine after entering a skilled nursing facility had a 24% lower risk of being diagnosed with dementia over four years compared to unvaccinated peers. The study analyzed United States — Medicare data and electronic health records from 509,926 adults aged 66 and older admitted to more than 5,500 U.S. skilled nursing facilities between 2017 and 2022. Only 8,843 participants received at least one dose of Shingrix. Dementia developed in 18.8% of vaccinated participants versus 24.6% of unvaccinated, suggesting about one in 17 dementia cases could potentially be prevented. The study, led by Kaley Hayes of Brown University, used target trial emulation to strengthen causal inference but cannot prove causation. Vaccinated individuals were slightly younger and healthier, and the authors adjusted for these factors. The findings align with earlier studies on older shingles vaccines. The study was funded by GSK plc, the manufacturer of Shingrix, which had no control over the research. Further clinical trials are needed to confirm the link.

50 Kaley Hayes led study
40 GSK plc funded study
20 United States — Medicare provided data
10 Edmundo Rodriguez-Frias commented on study
10 United States hosted study
stock
Manufacturer of Shingrix and funder of the study. Positive findings could enhance its vaccine franchise and revenue prospects.
Importance 80.0 Sentiment 70.0
per
Lead author; her work gains visibility and may influence future research directions.
Importance 70.0 Sentiment 40.0
govactor
Provided claims data; central to the study's methodology.
Importance 50.0 Sentiment 20.0
cnt
Setting of the study; potential public health implications for its aging population.
Importance 40.0 Sentiment 20.0
govactor
Collaborating institution; contributed to the research.
Importance 30.0 Sentiment 20.0
per
Provided expert commentary; minor role.
Importance 20.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.